CD28/OX40 Bispecific Antibodies for Solid Organ Transplant Rejection Treatment

ChangeBridge: Patent Apps - Therapeutics (A61P)

Published April 2nd, 2026

Detected April 3rd, 2026

Summary

The USPTO published patent application US20260092113A1, filed by Bristol-Myers Squibb, covering methods for treating solid organ transplant rejection using CD28/OX40 bispecific antibodies. The application (No. 19237572) claims a multispecific binding protein with a VHH domain targeting CD28 and a VH/VL domain targeting OX40. Inventors include Rami Lissilaa, Benjamin Suratt, and Jessica Voss.

View original document View source feed page

What changed

The USPTO published a patent application for a novel therapeutic approach to solid organ transplant rejection using bispecific antibodies. The invention comprises multispecific binding proteins combining an immunoglobulin single variable domain (VHH) with binding specificity to CD28 and a conventional VH/VL domain targeting OX40, administered to prevent or treat transplant rejection. The application is classified under C07K 16/2818 and C07K 16/2878.

Pharmaceutical and biotechnology companies developing transplant therapeutics should review the application scope for freedom-to-operate considerations. This is a published patent application with no compliance requirements or deadlines; it represents intellectual property filing activity rather than regulatory action.

Source document (simplified)

← USPTO Patent Applications

TREATMENT OF SOLID ORGAN TRANSPLANT SUBJECTS WITH CD28/OX40 BISPECIFIC ANTIBODIES

Application US20260092113A1 Kind: A1 Apr 02, 2026

Inventors

Rami LISSILAA, Benjamin SURATT, Jessica VOSS

Abstract

Provided herein are methods for the treatment or prevention of solid organ transplant rejection in a subject in need thereof, comprising administering to the subject a multispecific binding proteins comprising (a) a first antigen binding domain (ABD) comprising an immunoglobulin single variable domain (ISVD) (e.g., VHH) with binding specificity to CD28; and (b) a second ABD comprising an immunoglobulin heavy chain variable domain (VH) and an immunoglobulin light chain variable domain (VL) with binding specificity to OX40.